Dambkowski Carl, Chief Medical Officer at both Apogee Therapeutics (APGE) and Oruka Therapeutics (ORKA), has been a consistent seller of company stock over the past several months, with no open-market purchases recorded in his recent Form 4 filings. His transaction history shows a clear disposition bias, with total sell value exceeding $18.7 million across 55 trades, all executed through open-market sales (code S) or option exercises (code M) followed by sales. The most recent activity, dated July 14, 2026, was a gift of APGE shares valued at zero, but the preceding weeks were dominated by substantial sell transactions.
The largest concentration of selling occurred in June and May 2026, with APGE trades on June 22 totaling $3.5 million and ORKA trades on May 21 reaching a combined $6.2 million across three separate sale transactions. Smaller but recurring APGE sales occurred on a near-monthly cadence—April 1 ($466,619), May 6 ($462,784), June 3 ($432,905), and July 1 ($730,070)—each paired with an option exercise of $94,297.50, suggesting a systematic pattern of exercising and immediately liquidating vested options. ORKA sales on June 11 and June 12 added another $2.45 million, while a June 2 grant (code A) of ORKA shares at zero value represented the only acquisition during the period.
The absence of any open-market purchases (code P) across the entire filing history is notable, as every transaction involving cash flow has been a sale. The pattern of option exercises paired with same-day sales, combined with the lack of any buy-side conviction, indicates that Carl has been steadily monetizing his equity compensation rather than accumulating additional positions. The most recent APGE sale on July 1, 2026, at $730,070, suggests this selling trend has continued into the current quarter without interruption.
AI-assisted summary